Ken Griffin Cardiff Oncology, Inc. Call Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	SELL	$2.05 - $2.77 $36,900 - $49,860	-18,000 Reduced 75.31%	5,900 $15,000
Q2 2024 Aug 14, 2024	SELL	$2.22 - $5.89 $5,772 - $15,314	-2,600 Reduced 9.81%	23,900 $53,000
Q1 2024 May 15, 2024	BUY	$1.46 - $5.91 $27,740 - $112,290	19,000 Added 253.33%	26,500 $141,000
Q4 2023 Feb 14, 2024	SELL	$0.96 - $1.55 $12,288 - $19,840	-12,800 Reduced 63.05%	7,500 $11,000
Q3 2023 Nov 14, 2023	BUY	$1.38 - $2.18 $14,075 - $22,236	10,200 Added 100.99%	20,300 $28,000
Q2 2023 Aug 14, 2023	BUY	$1.37 - $1.95 $8,768 - $12,480	6,400 Added 172.97%	10,100 $14,000
Q1 2023 May 15, 2023	BUY	$1.45 - $2.09 $1,740 - $2,508	1,200 Added 48.0%	3,700 $6,000
Q4 2022 Feb 14, 2023	SELL	$1.22 - $1.66 $65,026 - $88,478	-53,300 Reduced 95.52%	2,500 $3,000
Q3 2022 Nov 14, 2022	BUY	$1.54 - $3.21 $85,932 - $179,118	55,800 New	55,800 $86,000

12.3M

813K

91.1K

Ticker CRDF
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,334,900
Market Cap $185M
Description
Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; meta...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.